Association of tissue promoter methylation levels of APC, TGFβ2, HOXD3 and RASSF1A with prostate cancer progression.
about
Epigenetic effects of green tea polyphenols in cancerImpact of glutathione-S-transferases (GST) polymorphisms and hypermethylation of relevant genes on risk of prostate cancer biochemical recurrence: a meta-analysisValidation study of genes with hypermethylated promoter regions associated with prostate cancer recurrence.DNA methylation gene-based models indicating independent poor outcome in prostate cancer.Methylation of APC and GSTP1 in non-neoplastic tissue adjacent to prostate tumour and mortality from prostate cancer.GSTP1 promoter methylation is associated with recurrence in early stage prostate cancer.RASSF1 tumor suppressor gene in pancreatic ductal adenocarcinoma: correlation of expression, chromosomal status and epigenetic changes.Clinical utility of RASSF1A methylation in human malignancies.Epigenetic regulation of prostate cancerDNA hypomethylation affects cancer-related biological functions and genes relevant in neuroblastoma pathogenesis.Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer.Strategies for discovery and validation of methylated and hydroxymethylated DNA biomarkers.Prostate cancer: the need for biomarkers and new therapeutic targets.Aberrant DNA methylation of G-protein-coupled bile acid receptor Gpbar1 (TGR5) is a potential biomarker for hepatitis B Virus associated hepatocellular carcinoma.Novel multiplex MethyLight protocol for detection of DNA methylation in patient tissues and bodily fluids.Wnt and SHH in prostate cancer: trouble mongers occupy the TRAIL towards apoptosis.Diagnostic and prognostic molecular biomarkers for prostate cancer.APC gene hypermethylation and prostate cancer: a systematic review and meta-analysis.Methylation markers for prostate cancer prognosis: a systematic review.Prognostic DNA methylation markers for prostate cancer.The potential of DNA modifications as biomarkers and therapeutic targets in oncology.Promoter CpG-Site Methylation of the KAI1 Metastasis Suppressor Gene Contributes to Its Epigenetic Repression in Prostate Cancer.Promoter hypermethylation of tumor suppressor genes correlates with tumor grade and invasiveness in patients with urothelial bladder cancer.Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer.Comparative effects of soy phytoestrogens and 17β-estradiol on DNA methylation of a panel of 24 genes in prostate cancer cell lines.Control of epigenetic states by WT1 via regulation of de novo DNA methyltransferase 3A.DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer.A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: a retrospective cohort study.LINE-1 methylation status in prostate cancer and non-neoplastic tissue adjacent to tumor in association with mortality.DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence.Distinct DNA methylation alterations are associated with cribriform architecture and intraductal carcinoma in Gleason pattern 4 prostate tumors.TGFB2 and BCL2L11 methylation in male laryngeal cancer patientsCorrelation of HOXD3 promoter hypermethylation with clinical and pathologic features in screening prostate biopsies.Frequent DNA Hypermethylation at the RASSF1A and APC Gene Loci in Prostate Cancer Patients of Pakistani Origin.DNA methylome and the complexity of discovering prostate cancer biomarkers.Integrated analysis of epigenomic and genomic changes by DNA methylation dependent mechanisms provides potential novel biomarkers for prostate cancer.APC methylation predicts biochemical recurrence of patients with prostate cancer: a meta-analysis.The association between RASSF1A promoter methylation and prostate cancer: evidence from 19 published studies.HOXA9, ISL1 and ALDH1A3 methylation patterns as prognostic markers for nonmuscle invasive bladder cancer: array-based DNA methylation and expression profiling.Epigenetic biomarkers: Current strategies and future challenges for their use in the clinical laboratory.
P2860
Q24568216-925F1C77-81F7-42B3-ABC5-E0B068F8B5A8Q28533760-8EB7A40F-DF70-4BFF-A9D0-343C1E1A75C7Q30582750-E372505B-3980-491D-AEAF-8E0B4C1E896FQ34174356-B2B56AF6-B7BD-40BD-B82C-FC8B00052AACQ34847101-1EF0589A-6B32-4C86-98F1-9E9C80CD52DAQ35322421-A4F8D94F-0EBF-44BA-ABD1-C377F35C5049Q35891000-6FEA8A11-D3FF-4631-8B60-CD8F7429EE75Q35909621-F18762CD-53E3-48A8-96E3-71713893F11CQ36001910-03A2E543-6FF7-4CC2-8D8D-BAA440665A19Q36380887-EDB2A8F3-C6C4-4CF6-AFC9-379B3CA223E4Q36447329-A4D88BDF-ABFD-4543-A9AF-4DBA4A5E8D8AQ36530688-1938AB3C-A5A1-44E8-A5D6-6A314748C96EQ37476043-1ED18335-C372-4990-AE91-5F3B26A3079DQ37488688-172E9899-AAF4-40C7-8C7A-E3D370C87B1AQ37653469-7B8AA7C6-89E4-40A4-B9F9-90A9F3D7C967Q37942610-4D7F4DE7-B506-4249-AC74-F56D02178294Q37972703-82DBE821-EAF9-4448-A4E9-208F8C383599Q38072660-173EE3B3-18B3-4557-A4B1-A053252C13E6Q38116745-01DEE194-B964-40C1-9295-4A0417314668Q38252624-77C62463-9D0D-4575-BACF-B29C6344AAA9Q38591064-A4FE851A-FF4F-4B55-BBC2-AD0C7DA05D1AQ38733030-C17F796C-B683-4601-99FE-AAC974181195Q38981120-53CF3EB5-1A42-44BA-AE1D-3E04825A3C62Q38983831-A4F1C280-E44F-4FB9-AC1E-6A99C62ABEB0Q39014316-6F34A8DD-7066-45DF-9C67-69F0C2123EDDQ39264413-25C26822-6E8E-4B5C-AF2A-0BF806B35EB5Q39552467-EDE16572-B43E-4E0D-A06E-EED3700B2097Q39581362-9EE112A2-554B-47AB-AD45-3E44476642A2Q40454546-7F09C31C-E8AA-4EC3-A3A3-63F537D0ED9EQ40581966-0517B589-DA3A-4981-9F38-5E6916F7E1ADQ40977912-BD453F66-07BE-4FF2-8231-B2965C52C671Q41195778-5CD107D4-86BF-485B-BB1E-4E5AAEB0C578Q41767078-C60F4522-6EDE-4737-8AD0-E56D29D4928BQ41845384-14D13E89-C3AB-4F05-9CA7-0F318BF0DF38Q42140874-65F24606-990C-42A8-856F-6C81064919A7Q42950544-758E7D30-D5CA-49C8-B7BA-D243FAB0EE28Q43156796-0313C8FD-CD31-4A6D-B682-7579BEDE9DD1Q44538170-C905A9FC-6C10-4EC1-A859-A1D202388D20Q45716446-FE2EBCB5-88A6-48C2-A22A-430A02E9F9D2Q47789662-7608567D-28D7-47B0-BF5D-483BB8384448
P2860
Association of tissue promoter methylation levels of APC, TGFβ2, HOXD3 and RASSF1A with prostate cancer progression.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Association of tissue promoter ...... h prostate cancer progression.
@en
Association of tissue promoter ...... h prostate cancer progression.
@nl
type
label
Association of tissue promoter ...... h prostate cancer progression.
@en
Association of tissue promoter ...... h prostate cancer progression.
@nl
prefLabel
Association of tissue promoter ...... h prostate cancer progression.
@en
Association of tissue promoter ...... h prostate cancer progression.
@nl
P2093
P2860
P356
P1476
Association of tissue promoter ...... h prostate cancer progression.
@en
P2093
Bharati Bapat
Hilmi Ozcelik
John Trachtenberg
Ken J Kron
Laurent Briollais
Liyang Liu
Michael E Nesbitt
Neil E Fleshner
Nino Demetrashvili
Vaijayanti V Pethe
P2860
P304
P356
10.1002/IJC.25908
P577
2011-04-13T00:00:00Z